Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
06 Setembro 2023 - 10:00AM
Artelo Biosciences, Inc. (Nasdaq:
ARTL)
, a clinical-stage pharmaceutical
company focused on modulating lipid-signaling pathways to develop
treatments for people living with cancer, pain, and neurological
conditions, today announced that Myles Osborn, Medicinal Chemist at
Artelo Biosciences, will be presenting at the 6th
Cannabinoid-Derived Drug Development Summit being held September
11-13, 2023 at the Hilton Boston Back Bay hotel in Boston, MA.
Mr. Osborn’s presentation, titled “Improving Cannabidiol for
Oral Solid Dosage Form Drug Products,” is scheduled for 1:45 p.m.
Eastern Time on Tuesday, September 12, 2023. During the
presentation, Mr. Osborn will discuss how co-crystallization
assists with improving the pharmaceutical properties of a drug,
including solubility, dissolution and absorption as well as present
data on ART12.11, Artelo’s patented CBD cocrystal, in preclinical
chronic stress models measuring anxiety, depression, sociability,
and cognition.
To register for the event, please visit: 6th Cannabinoid-Derived
Drug Development Summit.
About ART12.11ART12.11 is a proprietary
cocrystal composition of cannabidiol (CBD). It is isolated as a
single crystalline form that offers biopharmaceutic advantages over
compositions of CBD that exhibit solid polymorphism (i.e., the
ability to manifest different forms). Preclinical studies of
ART12.11 have exhibited superior pharmacokinetics and improved
efficacy compared to other forms of CBD. With superior
pharmaceutical properties and preclinical results, Artelo believes
a more consistent and improved bioavailability profile may
ultimately lead to improved safety and efficacy in humans, thus
making ART12.11 a preferred CBD pharmaceutical composition.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission, including our ability to raise
additional capital in the future. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by
applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Artelo Biosciences (NASDAQ:ARTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024